Stealth BioTherapeutics Corp [NASDAQ: MITO] surged by $0.42 during the normal trading session on Thursday and reaching a high of $2.45 during the day while it closed the day at $1.62. The company report on May 6, 2021 that Stealth BioTherapeutics Showcases Data for Elamipretide in Dry Age-Related Macular Degeneration at the 2021 ARVO Annual Meeting.
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced the presentation of new data from a post hoc analysis of the Phase 1 ReCLAIM study evaluating elamipretide in patients with non-central geographic atrophy (GA) and high risk drusen associated with dry age-related macular degeneration (AMD). The data, presented at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting, showed that for patients with GA treated with elamipretide for 24-weeks, improvements from baseline in low light visual acuity (LLVA), which is the primary efficacy endpoint in Stealth’s fully enrolled Phase 2 ReCLAIM-2 trial, were significantly correlated to baseline assessments of mitochondrial health in the ellipsoid zone (EZ). The EZ is a mitochondria-rich area of the retina which supports photoreceptor function and is attenuated in dry AMD. EZ imaging assessments were conducted using optical coherence tomography (OCT) and included pan-macular EZ-retinal pigment endothelium cell (RPE) volume and macular percentage of EZ-RPE attenuation. Improvements in LLVA were significantly correlated to both baseline EZ-RPE volume and EZ-RPE attenuation, with eyes gaining two or more lines showing significantly less EZ-RPE attenuation and percentage area of macular GA at baseline.
“Based on the data presented showing an association between outer retinal features and treatment response to elamipretide, this approach to imaging biomarker interrogation may provide a unique opportunity for clinical trial enrichment and identification of eyes that are more likely to benefit from treatment,” noted Dr. Justis Ehlers, the Norman C. and Donna L. Harbert Endowed Chair of Ophthalmic Research at Cole Eye Institute at Cleveland Clinic. “These findings may suggest that there may be a ‘retinal reserve’ that is required and potentially measurable that provides a greater chance at treatment response.”.
Stealth BioTherapeutics Corp stock has also gained 31.71% of its value over the past 7 days. However, MITO stock has declined by -7.43% in the 3 months of the year. Over the past six months meanwhile, it has gained 14.89% and gained 8.36% year-on date.
The market cap for MITO stock reached $93.12 million, with 51.25 million shares outstanding and 5.03 million shares in the current float. Compared to the average trading volume of 370.10K shares, MITO reached a trading volume of 203840434 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Stealth BioTherapeutics Corp [MITO]:
ROTH Capital have made an estimate for Stealth BioTherapeutics Corp shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 14, 2020. The new note on the price target was released on April 02, 2020, representing the official price target for Stealth BioTherapeutics Corp stock. Previously, the target price had yet another drop from $21 to $5, while H.C. Wainwright kept a Neutral rating on MITO stock.
The Average True Range (ATR) for Stealth BioTherapeutics Corp is set at 0.18
MITO stock trade performance evaluation
Stealth BioTherapeutics Corp [MITO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 31.71. With this latest performance, MITO shares gained by 13.29% in over the last four-week period, additionally plugging by 14.89% over the last 6 months – not to mention a drop of -4.99% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MITO stock in for the last two-week period is set at 64.06, with the RSI for the last a single of trading hit 73.95, and the three-weeks RSI is set at 57.99 for Stealth BioTherapeutics Corp [MITO]. The present Moving Average for the last 50 days of trading for this stock 1.4838, while it was recorded at 1.2960 for the last single week of trading, and 1.5544 for the last 200 days.
Stealth BioTherapeutics Corp [MITO]: An insightful look at the core fundamentals
Return on Total Capital for MITO is now -302.89, given the latest momentum, and Return on Invested Capital for the company is -1,364.61. Return on Equity for this stock declined to -1,666.63, with Return on Assets sitting at -129.71.
Reflecting on the efficiency of the workforce at the company, Stealth BioTherapeutics Corp [MITO] managed to generate an average of -$1,981,237 per employee.Stealth BioTherapeutics Corp’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.70 and a Current Ratio set at 1.70.
Earnings per share (EPS) analysis for Stealth BioTherapeutics Corp [MITO] stock
With the latest financial reports released by the company, Stealth BioTherapeutics Corp posted -0.04/share EPS, while the average EPS was predicted by analysts to be reported at -0.09/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 55.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MITO.
Stealth BioTherapeutics Corp [MITO]: Insider Ownership positions
Positions in Stealth BioTherapeutics Corp stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 9 institutional holders increased their position in Stealth BioTherapeutics Corp [NASDAQ:MITO] by around 654,977 shares. Additionally, 4 investors decreased positions by around 284,866 shares, while 3 investors held positions by with 53,244 shares. The mentioned changes placed institutional holdings at 993,087 shares, according to the latest SEC report filing. MITO stock had 6 new institutional investments in for a total of 154,398 shares, while 2 institutional investors sold positions of 273,136 shares during the same period.